Taking the Long View on Pharma’s Reputation Management

Posted by Pratap Khedkar on Tue, Aug 08, 2017

This is the second post in a two-part series on reputation management in the pharmaceutical industry. 

I concluded my last post by saying that the actions of one company can affect the public’s perceptions of many. That, in a nutshell, is a primary contributor to the pharmaceutical industry’s reputation problem. Over the past year, for example, a few companies’ drastic drug price increases have shaped the public’s perceptions of pharmaceutical pricing overall—so much so that, in an attempt to counteract negative perceptions, many pharma companies have publicly announced plans to keep their own price increases reined in. Last October, Allergan CEO Brent Saunders promised to avoid any price increases greater than 10% per year, and a half dozen or so companies followed suit. 


>
Read More

Reputation Is Paramount, So What’s Holding Pharma Companies Back?

Posted by Pratap Khedkar on Tue, Aug 01, 2017

This is the first post in a two-part series on reputation management in the pharmaceutical industry.

Recent polls and surveys demonstrate that the pharmaceutical industry’s reputation continues to be plagued by negative perceptions. While there have been some signs of improvement here and there over the past few years, many consumers still consider pharma’s reputation to be on par with the tobacco industry, positioning one product category that treats cancer just above a product category that causes it. A survey released in March 2017 by PatientView, a U.K.-based organization that researches patient groups globally, revealed that the drug industry’s reputation took a hit in 2016 following a five-year period of progress.


>
Read More

Discussing Patient Centricity’s Challenges and Opportunities

Posted by Pratap Khedkar on Wed, Jun 21, 2017

In my last blog post, I used the pharmaceutical industry’s quest for patient centricity as a jumping-off point to discuss how pharma companies need to focus on customer centricity, rethinking their commercial strategies to better address their many stakeholders in the evolving healthcare ecosystem. But since patients’ wellness is the pharmaceutical industry’s reason for being, patient centricity should remain pharma’s North Star. 


>
Read More

Patient Centricity Is Important, but Customer Centricity Is Imperative

Posted by Pratap Khedkar on Mon, May 01, 2017

Paul Darling co-authored this blog post with Pratap Khedkar.

Patient centricity was the rallying cry at last month’s eyeforpharma event in Philadelphia, with many speakers echoing the sentiment that the patient is at the center of what we do. That’s great in theory, and it has always been true for pharmaceutical products, but here’s one of the main reasons why patient centricity remains more of a talking point than standard business practice: The pharmaceutical industry has little control over ensuring that a patient benefits from a particular medicine. The patient may be at the center, but pharma is at the periphery.


>
Read More

My DC Visit Resulted in More Clarity Than Questions: Four Takeaways

Posted by Pratap Khedkar on Fri, Feb 10, 2017

Like so many millions of people—or so few, depending on whom you ask—I spent a couple of days in our nation’s capital during the Trump administration’s first week, but I wasn’t out on the National Mall with a cleverly worded sign. I was there to join other healthcare industry leaders, thought leaders and pundits as they discussed the evolving healthcare environment. I wanted to get a sense for what may be coming down the pike, and based on what I heard, it seems that the only constant is change—and pharmaceutical leaders better get ready to help shape this change. Here are four of my takeaways:


>
Read More